Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome

被引:8
|
作者
Kumar, Achal [1 ]
Tripathi, Deepak [2 ]
Paliwal, Vimal Kumar [1 ]
Neyaz, Zafar [3 ]
Agarwal, Vikas [2 ]
机构
[1] SGPGIMS, Dept Neurol, Lucknow 226014, Uttar Pradesh, India
[2] SGPGIMS, Dept Clin Immunol, Lucknow 226014, Uttar Pradesh, India
[3] SGPGIMS, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India
关键词
Lennox-Gastaut syndrome; refractory epilepsy; P-glycoprotein; multidrug resistance gene; MEDICALLY INTRACTABLE EPILEPSY; FOCAL CORTICAL DYSPLASIA; MULTIDRUG TRANSPORTERS; RESISTANCE PROTEINS; GENE-EXPRESSION;
D O I
10.1177/0883073814532545
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Mechanism of seizure refractoriness to antiepileptic drugs in children with Lennox-Gastaut syndrome is not known. Efflux of antiepileptic drugs due to increased expression/function of P-glycoprotein, a multidrug efflux transporter protein on the cell surface is a proposed mechanism. The authors studied the expression/function of P-glycoprotein on peripheral blood mononuclear cells of 29 children with Lennox-Gastaut syndrome, 23 children with other epilepsies, and 19 healthy children. The authors found a higher P-glycoprotein expression/function in Lennox-Gastaut syndrome, a higher percent positive cells as compared to children with other epilepsy (P < 0.001) and to healthy controls (P = 0.012), higher P-glycoprotein expression as compared to healthy controls (P = 0.003), a higher total P-glycoprotein expression (relative florescence intensity x percent positive cells) as compared to children with other epilepsies (P < 0.001) and healthy controls (P < 0.001), and a higher P-glycoprotein function as compared to children with other epilepsies (P = 0.001) and healthy controls (P = 0.002). These findings may explain seizure refractoriness to anti-epileptic drugs in Lennox-Gastaut syndome.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [1] EFFECT OF ANTIEPILEPTIC DRUGS IN ELECTROCLINICAL TYPES OF EPILEPTIC SEIZURES IN LENNOX-GASTAUT SYNDROME
    GERALDOSPECIALI, J
    PIERRELISON, M
    ARQUIVOS DE NEURO-PSIQUIATRIA, 1977, 35 (03) : 218 - 227
  • [2] Budget Impact Analysis of Antiepileptic Drugs for Lennox-Gastaut Syndrome
    Skornicki, Michelle
    Clements, Karen M. .
    O'Sullivan, Amy K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (04): : 400 - 406
  • [3] Management of Seizures in Lennox-Gastaut Syndrome
    Crumrine, Patricia K.
    PEDIATRIC DRUGS, 2011, 13 (02) : 107 - 118
  • [4] Management of Seizures in Lennox-Gastaut Syndrome
    Patricia K. Crumrine
    Pediatric Drugs, 2011, 13 : 107 - 118
  • [5] Eating seizures in Lennox-Gastaut syndrome
    Lee, IH
    Kwan, SY
    Su, MS
    EUROPEAN NEUROLOGY, 2001, 45 (02) : 123 - 125
  • [6] ELECTROCLINICAL SEIZURES IN LENNOX-GASTAUT SYNDROME
    YAQUB, BA
    EPILEPSIA, 1993, 34 (01) : 120 - 127
  • [7] BUDGET IMPACT ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
    Skornicki, M.
    Clements, K. M.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A141 - A142
  • [8] Rufinamide: A New Antiepileptic Medication for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
    Wisniewski, Christopher S.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (04) : 658 - 667
  • [9] CINROMIDE IN THE TREATMENT OF SEIZURES IN THE LENNOX-GASTAUT SYNDROME
    LOCKMAN, LA
    ROTHNER, AD
    ERENBERG, G
    WRIGHT, FW
    CLOUTIER, G
    GEIGER, EH
    EPILEPSIA, 1981, 22 (02) : 241 - 241
  • [10] Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome
    Clements, Karen M.
    Skornicki, Michelle
    O'Sullivan, Amy K.
    EPILEPSY & BEHAVIOR, 2013, 29 (01) : 184 - 189